一. 課題組簡(jiǎn)介

課題組具有豐富的腫瘤學(xué)、免疫學(xué)、生物力學(xué)研究經(jīng)驗，主攻腫瘤免疫、生物力學(xué)腫瘤免疫、腫瘤免疫治療方向，通過(guò)學(xué)科交叉研究，從免疫學(xué)、生物力學(xué)角度等探究腫瘤發(fā)生發(fā)展的分子機理以及腫瘤與免疫微環(huán)境的互作，以期探尋全新的腫瘤免疫療法。

課題組現有博士研究生一名，碩士研究生兩名，北京協(xié)和醫院聯(lián)合培養博士生一名。

二. 課題組長(cháng)介紹

劉玉英，中國醫學(xué)科學(xué)院基礎醫學(xué)研究所藥理系，研究員，博士生導師。博士畢業(yè)于中國醫學(xué)科學(xué)院藥物研究所；畢業(yè)后在美國南卡羅萊納州醫科大學(xué)進(jìn)行博士后，從事腫瘤治療研究；回國后加入中國醫學(xué)科學(xué)院基礎醫學(xué)研究所。

主持多項國自然基金項目，包括國自然專(zhuān)項、重大研究計劃培育、國際合作、面上項目等。在Cancer cell、Nat Immunol、Nat Cell Biol、Nat Biomed Eng、Sci Immunol、Cell Res、J Clin Invest、Nat Commun、Cancer Res 、EMBO J、Nuc Acid Res等國際主流雜志上以通訊作者或第一作者（共同）發(fā)表多篇研究論文，引用2600多次。

三. 代表性論文 (僅列出近五年通訊或第一（共同）作者的學(xué)術(shù)論文)

1. Jiadi Lv, Yuying Liu, Siqi Mo, Yabo Zhou, Fengye Chen, Feiran Cheng, Cong Li, Dilizhatai Saimi, Mengyu Liu, Huafeng Zhang, Ke Tang, Jingwei Ma, Zhenfeng Wang, Qiangqiang Zhu, Wei-Min Tong & Bo Huang. Gasdermin E mediates resistance of pancreatic adenocarcinoma to enzymatic digestion through a YBX1–mucin pathway. Nat Cell Biol. 2022;24:364–372. (IF=28.824)
2. Liu Y, Zhou N, Zhou L, Wang J, Zhou Y, Zhang T, Fang Y, Deng J, Gao Y, Liang X, Lv J, Wang Z, Xie J, Xue Y, Zhang H, Ma J, Tang K, Fang Y, Cheng F, Zhang C, Dong B, Zhao Y, Yuan P, Gao Q, Zhang H, Xiao-Feng Qin F, Huang B.. IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor. Nat Immunol. 2021;22(3):358-369. (IF=25.606)
3. Lv J, Liu Y, Cheng F, Li J, Zhou Y, Zhang T, Zhou N, Li C, Wang Z, Ma L, Liu M, Zhu Q, Liu X, Tang K, Ma J, Zhang H, Xie J, Fang Y, Zhang H, Wang N, Liu Y*, Huang B*. Cell softness regulates tumorigenicity and stemness of cancer cells. EMBO J. 2021;40:e106123. (IF=11.598)
4. Liu Y*, Zhang T, Zhang H, Li J, Zhou N, Fiskesund R, Chen J, Lv J, Ma J, Zhang H, Tang K, Cheng F, Zhou Y, Zhang X, Wang N, Huang B*. Cell softness prevents cytolytic T cell killing of tumor-repopulating cells. Cancer Res. 2021;81:476-488. (IF=12.701)
5. Lv J, Yu P, Wang Z, Deng W, Bao L, Liu J, Li F, Zhu Q, Zhou N, Lv Q, Wang G, Wang S, Zhou Y, Song J, Tong WM, Liu Y*, Qin C*, Huang B*. ACE2 expression is regulated by AhR in SARS-CoV-2-infected macaques. Cell Mol Immunol. 2021;18(5):1308-1310. (IF=11.53)
6. Lv J, Wang Z, Qu Y, Zhu H, Zhu Q, Tong W, Bao L, Lv Q, Cong J, Li D, Deng W, Yu P, Song J, Tong WM, Liu J*, Liu Y*, Qin C*, Huang B*. Distinct uptake, amplification, and release of SARS-CoV-2 by M1 and M2 aleolar macrophages. Cell Discov. 2021;7:24. (IF=10.849)
7. Liu Y, Lv J, Liu J, Li M, Xie J, Lv Q, Deng W, Zhou N, Zhou Y, Song J, Wang P, Qin C, Tong WM, Huang B. Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19. Cell Res. 2020;30:1078-1087. (IF=25.617)
8. Gao Y, Zhang H, Zhou N, Xu P, Wang J, Gao Y, Jin X, Liang X, Lv J, Zhang Y, Tang K, Ma J, Zhang H, Xie J, Yao F, Tong W, Liu Y*, Wang X*, Huang B*. Methotrexate-loaded tumour-cell-derived microvesicles can relieve biliary obstruction in patients with extrahepatic cholangiocarcinoma. Nat Biomed Eng. 2020;4:743-753. (IF=25.671)
9. Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, Liu M, Zhou N, Lv J, Tang K, Xie J, Gao Y, Cheng F, Zhou Y, Zhang Z, Hu Y, Zhang X, Gao Q, Zhang Y, Huang B. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020;5(43):eaax7969. (IF=17.727)
10. Liu Y. et al. Visualization of perforin/gasdermin/complement-formed pores in real cell membranes using atomic force microscopy. Cell Mol Immunol. 2019;16:611-620. (IF=8.484)
11. Liu Y, Liang X, Dong W, Fang Y, Lv J, Zhang T, Fiskesund R, Xie J, Liu J, Yin X, Jin X, Chen D, Tang K, Ma J, Zhang H, Yu J, Yan J, Liang H, Mo S, Cheng F, Zhou Y, Zhang H, Wang J, Li J, Chen Y, Cui B, Hu ZW, Cao X, Xiao-Feng Qin F, Huang B. Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation. Cancer Cell 2018;33:480-494. (IF= 31.743)
12. Liu Y, Lv J, Liu J, Liang X, Jin X, Xie J, Zhang L, Chen D, Fiskesund R, Tang K, Ma J, Zhang H, Dong W, Mo S, Zhang T, Cheng F, Zhou Y, Jia Q, Zhu B, Kong Y, Guo J, Zhang H, Hu ZW, Cao X, Qin FX, Huang B. STAT3/p53 pathway activation disrupts IFN-beta-induced dormancy in tumor-repopulating cells. J Clin Invest. 2018;128:1057-1073. (IF=14.808)
13. Liu Y, Lv J, Liang X, Yin X, Zhang L, Chen D, Jin X, Fiskesund R, Tang K, Ma J, Zhang H, Dong W, Mo S, Zhang T, Cheng F, Zhou Y, Xie J, Wang N, Huang B. Fibrin Stiffness Mediates Dormancy of Tumor-Repopulating Cells via a Cdc42-Driven Tet2 Epigenetic Program. Cancer Res. 2018;78:3926-3937. (IF=12.701)
14. Liu Y, Liang X, Yin X, Lv J, Tang K, Ma J, Ji T, Zhang H, Dong W, Jin X, Chen D, Li Y, Zhang S, Xie HQ, Zhao B, Zhao T, Lu J, Hu ZW, Cao X, Qin FX, Huang B. Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-gamma-induced immunologic dormancy of tumor-repopulating cells. Nat Commun 2017;8:15207. (IF=14.919)

四. 基金申請

(1) 國家自然科學(xué)基金專(zhuān)項基金，82341009，機械信號通路PIEZO1-GRHL3抑制T細胞介導的抗腫瘤生物力學(xué)研究，2023-03至2026-02，142萬(wàn)，在研，主持

(2) 國家自然科學(xué)基金重大培育項目，92169101，新冠肺炎治療新策略：細胞微顆粒遞送病毒進(jìn)入肺泡巨噬細胞降解，2022-01至2024-12，62萬(wàn)，在研，主持

(3) 國家自然科學(xué)基金國際合作項目，82061148014，干性腫瘤細胞利用物理軟性逃避T細胞殺傷機制與治療策略，2020-10至2023-09，200萬(wàn)， 在研，主持

(4) 國家自然基金面上項目，81773062，IFN-β激活I(lǐng)DO1-Kyn-AhR信號通路調節腫瘤再生細胞休眠；2018-01-01至2021-12-31，58萬(wàn)元，已結題，主持

(5) 中國醫學(xué)科學(xué)院醫學(xué)與健康科技創(chuàng )新工程項目-新型冠狀病毒肺炎科研攻關(guān)先導專(zhuān)項，2020-I2M-CoV19-007，新冠病毒觸發(fā)炎癥風(fēng)暴的機制研究，2020-06至2021-12，150萬(wàn)元，已結題，主持

五. 獲得學(xué)術(shù)獎勵

中國醫學(xué)科學(xué)院北京協(xié)和醫學(xué)院科 青年創(chuàng )新獎

六. 專(zhuān)利申請（已經(jīng)授權）

(1) 檢測Kyn含量的試劑的應用

(2) 一種采用原子力顯微鏡檢測細胞表面孔洞的方法

(3) Method for detecting cell surface holes using atomic force microscope

(4) 一種含有轉運蛋白抑制劑的藥物、藥物組合物及用途